NCT02303431 Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study Status COMPLETED Phase PHASE1
NCT02299661 Pilot PK/PD Study of DS-1093a in Patients With Chronic Kidney Disease Status COMPLETED Phase PHASE1
NCT02266940 Relative Bioavailability DS-1971a Suspension and Tablets and Food Effect on DS-1971a Tablets Status COMPLETED Phase PHASE1
NCT02261376 Effects of Age, Gender & Race on the Pharmacokinetics (PK)of DS-1971a Status COMPLETED Phase PHASE1
NCT02258880 Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke Status WITHDRAWN Phase PHASE2
NCT02249949 Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery Status COMPLETED Phase PHASE2
NCT02234583 An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia Status COMPLETED Phase PHASE3
NCT02152137 Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer Status COMPLETED Phase PHASE2
NCT02150733 Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment Status COMPLETED Phase PHASE1
NCT02142400 Multiple Ascending Dose Study of DS-1093 in Healthy Subjects Status COMPLETED Phase PHASE1
NCT02134015 Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung) Status TERMINATED Phase PHASE3
NCT02107885 Single Ascending Dose Study Using DS-1971 to Assess Safety, Tolerability, and Pharmacokinetics in Healthy Participants. Status COMPLETED Phase PHASE1
NCT02082548 Clinical Trial to Improve Treatment With Blood Thinners in Patients With Atrial Fibrillation Status COMPLETED Phase NA
NCT02076451 Open-label Study of DS-8273a to Assess Its Safety and Tolerability, and Assess Its Pharmacokinetic and Pharmacodynamic Properties in Subjects With Advanced Solid Tumors or Lymphomas Status COMPLETED Phase PHASE1
NCT02072434 Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF) Status COMPLETED Phase PHASE3